Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) EBITDA (2018 - 2025)

Serina Therapeutics' EBITDA history spans 8 years, with the latest figure at -$4.6 million for Q3 2025.

  • For Q3 2025, EBITDA fell 432.54% year-over-year to -$4.6 million; the TTM value through Sep 2025 reached -$21.6 million, down 1307.11%, while the annual FY2024 figure was -$17.0 million, 444.84% down from the prior year.
  • EBITDA for Q3 2025 was -$4.6 million at Serina Therapeutics, up from -$5.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $3.3 million in Q4 2023 and bottomed at -$5.9 million in Q1 2025.
  • The 5-year median for EBITDA is -$1.9 million (2021), against an average of -$2.2 million.
  • The largest annual shift saw EBITDA skyrocketed 283.56% in 2023 before it crashed 432.54% in 2025.
  • A 5-year view of EBITDA shows it stood at -$1.9 million in 2021, then grew by 4.55% to -$1.8 million in 2022, then surged by 283.56% to $3.3 million in 2023, then crashed by 269.64% to -$5.5 million in 2024, then increased by 17.12% to -$4.6 million in 2025.
  • Per Business Quant, the three most recent readings for SER's EBITDA are -$4.6 million (Q3 2025), -$5.6 million (Q2 2025), and -$5.9 million (Q1 2025).